118 related articles for article (PubMed ID: 25796755)
1. [How I treat...The choice between a sulphonylulrea and a gliptin to manage hyperglycaemia in type 2 diabetes].
Scheen AJ
Rev Med Liege; 2014 Sep; 69(9):476-84. PubMed ID: 25796755
[TBL] [Abstract][Full Text] [Related]
2. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
5. [2015 updated position statement of the management of hyperglycaemia in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Suisse; 2015 Aug; 11(483):1518, 1520-5. PubMed ID: 26502577
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
7. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
Nauck MA
Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Klarenbach S; Cameron C; Singh S; Ur E
CMAJ; 2011 Nov; 183(16):E1213-20. PubMed ID: 21969406
[TBL] [Abstract][Full Text] [Related]
9. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
10. Incorporating New Medications in Diabetes Care.
Comi RJ
Ann Intern Med; 2015 Nov; 163(9):719-20. PubMed ID: 26458033
[No Abstract] [Full Text] [Related]
11. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
12. Which oral agent to use when metformin is no longer effective?
Bannon M
QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
[No Abstract] [Full Text] [Related]
13. Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
Bagepally BS; Gurav YK; Anothaisintawee T; Youngkong S; Chaikledkaew U; Thakkinstian A
Value Health; 2019 Dec; 22(12):1458-1469. PubMed ID: 31806203
[TBL] [Abstract][Full Text] [Related]
14. Diabetes under control: Understanding oral antidiabetic agents.
Longo R
Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
[No Abstract] [Full Text] [Related]
15. Pharmacologic Agents Used to Treat Type 2 Diabetes.
Moran KJ; Burson R
Home Healthc Now; 2017; 35(7):394-395. PubMed ID: 28650371
[No Abstract] [Full Text] [Related]
16. A Sensitivity Analysis to Assess Bias Due to Selecting Subjects Based on Treatment Received.
Ertefaie A; Small D; Flory J; Hennessy S
Epidemiology; 2016 Mar; 27(2):e5-7. PubMed ID: 26628427
[No Abstract] [Full Text] [Related]
17. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
18. No better than less expensive drugs.
Perry TL; Lippman SS; McConnell M; Tejani AM
BMJ; 2012 Apr; 344():e2914. PubMed ID: 22531805
[No Abstract] [Full Text] [Related]
19. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
Freeman JS
J Am Osteopath Assoc; 2010 Sep; 110(9):528-37. PubMed ID: 20876838
[TBL] [Abstract][Full Text] [Related]
20. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
